2. Signaling Pathways
  3. Neuronal Signaling
  4. Glucosylceramide Synthase (GCS)

Glucosylceramide Synthase (GCS)

Glucosylceramide synthase (GCS), converting ceramide to glucosylceramide, catalyzes the first reaction of ceramide glycosylation in sphingolipid metabolism. This glycosylation by GCS is a critical step regulating the modulation of cellular activities by controlling ceramide and glycosphingolipids (GSLs). An increase of ceramide in response to stresses, such as chemotherapy, drives cells to proliferation arrest and apoptosis or autophagy; however, ceramide glycosylation promptly eliminates ceramide and consequently, these induced processes, thus protecting cancer cells. Furthermore, persistently enhanced ceramide glycosylation can increase GSLs, participating in selecting cancer cells to drug resistance. GCS is overexpressed in diverse drug-resistant cancer cells and in tumors of breast, colon, and leukemia that display poor response to chemotherapy. As ceramide glycosylation by GCS is a rate-limiting step in GSL synthesis, inhibition of GCS sensitizes cancer cells to anticancer drugs and eradicates cancer stem cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14885
    Eliglustat
    		Inhibitor 99.74%
    Eliglustat is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
    Eliglustat
  • HY-17020
    Miglustat
    		Inhibitor 99.95%
    Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.
    Miglustat
  • HY-16743
    Ibiglustat
    		99.86%
    Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat
  • HY-14885A
    Eliglustat hemitartrate
    		Inhibitor 99.27%
    Eliglustat hemitartrate is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
    Eliglustat hemitartrate
  • HY-17020A
    Miglustat hydrochloride
    		Inhibitor 99.97%
    Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor, with blood-brain barrier permeability. Miglustat hydrochloride can be used for the research of type I gaucher disease.
    Miglustat hydrochloride
  • HY-186121A
    Glucosylceramide synthase-IN-6
    		Inhibitor
    Glucosylceramide synthase-IN-6 (G3-3B) is a glucosylceramide synthase (GCS) inhibitor that can be used for the study of the diseases and disorders associated with GCS activity, such as lysosomal storage disorders.
    Glucosylceramide synthase-IN-6
  • HY-186121
    Glucosylceramide synthase-IN-5
    		Inhibitor
    Glucosylceramide synthase-IN-5 (G3-3) is a glucosylceramide synthase (GCS) inhibitor that can be used for the study of the diseases and disorders associated with GCS activity, such as lysosomal storage disorders.
    Glucosylceramide synthase-IN-5
  • HY-181989
    CAIF
    		Inhibitor
    CAIF is an irreversible, selective allosteric covalent inhibitor of ucosyltransferase 8 (FUT8) with an IC50 of 5.7 μM. CAIF inhibits core fucosylation modification in cancer cells, and suppresses the invasion and migration of cancer cells. CAIF is applicable for cancer research.
    CAIF
  • HY-12744
    Genz-123346 free base
    		Inhibitor 99.57%
    Genz-123346 free base is an orally available inhibitor of glucosylceramide synthase. Genz-123346 blocks the conversion of ceramide to glucosylceramide (GL1) and inhibits GM1 with an IC50 of 14 nM.
    Genz-123346 free base
  • HY-106392
    Lucerastat
    		98.90%
    Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study.
    Lucerastat
  • HY-116392D
    PDMP hydrochloride
    		Inhibitor 99.9%
    PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research.
    PDMP hydrochloride
  • HY-116392B
    DL-threo-PDMP hydrochloride
    		Inhibitor 99.40%
    DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites.
    DL-threo-PDMP hydrochloride
  • HY-N1938
    D(+)-Raffinose pentahydrate
    		Inhibitor 98.0%
    D(+)-Raffinose pentahydrate is an orally active inhibitor of LecA (Kd = 32 μM) and GtfC. D(+)-Raffinose pentahydrate reduces cyclic diguanylate (c-di-GMP) by increased activity of a c-di-GMP specific phosphodiesterase. D(+)-Raffinose pentahydrate interferes with GTF function. D(+)-Raffinose pentahydrate decreases IL-4 and IL-5 mRNA. D(+)-Raffinose pentahydrate exhibits biofilm-inhibitory activity against Pseudomonas aeruginosa and Streptococcus mutans and inhibits allergic airway eosinophilia.
    D(+)-Raffinose pentahydrate
  • HY-129411
    Sinbaglustat
    		99.83%
    Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions.
    Sinbaglustat
  • HY-114615
    AMP-Deoxynojirimycin
    		Inhibitor 99.7%
    AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor.
    AMP-Deoxynojirimycin
  • HY-16743A
    Ibiglustat (L-Malic acid)
    		98.65%
    Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat (L-Malic acid)
  • HY-E70157
    Fucosyltransferase 8
    Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans.
    Fucosyltransferase 8
  • HY-116392F
    D-threo-PDMP hydrochloride
    		Inhibitor 98.0%
    D-threo-PDMP hydrochloride is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP hydrochloride inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP hydrochloride inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP hydrochloride can be used to study diseases related to targeted glycosphingolipid metabolism.
    D-threo-PDMP hydrochloride
  • HY-16743B
    Ibiglustat succinate
    		99.71%
    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat succinate
  • HY-144267
    Glucosylceramide synthase-IN-2
    		98.62%
    Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research.
    Glucosylceramide synthase-IN-2
Cat. No. Product Name / Synonyms Application Reactivity